SCHEMBL2301749

SCHEMBL2301749

O=C(O)c1cccnc1OC(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 6/20 0.57
NAPRT Q6XQN6 2/20 0.55
TDP1 Q9NUW8 3/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 5/20 0.52
CYP3A4 P08684 2/20 0.52
MAPT P10636 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
BLM P54132 1/20 0.52
AGER Q15109 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RUNX1 Q01196 1/20 0.48
CYP2C9 P11712 2/20 0.43
MEN1 O00255 1/20 0.43
GMNN O75496 1/20 0.43
TTR P02766 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30087468 1.00 DHODH (0.57) DHODHNAPRTTDP1KDM4EALDH1A1
SCHEMBL29477666 0.84 RAB9A (0.55) DHODHNAPRTKDM4EALDH1A1MAPT
SCHEMBL20916924 0.84 RAB9A (0.55) DHODHNAPRTKDM4EALDH1A1MAPT
SCHEMBL7372993 0.83 TDP1 (0.52) DHODHTDP1KDM4EALDH1A1NPSR1
SCHEMBL30919007 0.81 NAPRT (0.50) DHODHNAPRTTDP1KDM4EALDH1A1
SCHEMBL456915 0.81 NAPRT (0.50) DHODHNAPRTTDP1KDM4EALDH1A1
SCHEMBL27313359 0.81 TDP1 (0.61) DHODHTDP1KDM4EALDH1A1MAPT
SCHEMBL24518039 0.80 NAPRT (0.49) DHODHNAPRTTDP1KDM4EALDH1A1
SCHEMBL3878750 0.80 NAPRT (0.49) DHODHNAPRTTDP1KDM4EALDH1A1
SCHEMBL29959517 0.78 KDM4E (0.57) DHODHNAPRTTDP1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
EP-2350008-A1 METHOD FOR THE PREPARATION OF FUNCTIONALIZED TRIHALOMETHOXY SUBSTITUTED PYRIDINES Bayer CropScience AG (DE) 2011-08-03 EP disclosed
US-4911753-A Herbicide AMERICAN CYANAMID COMPANY (US) 1990-03-27 US disclosed
US-4772311-A Herbicidal 2-(2-imidazolin-2-yl)fluoroalkoxy-, alkenyloxy- and alkynyloxy quinolines AMERICAN CYANAMID CO. (US) 1988-09-20 US disclosed
US-4647301-A Herbicidal 2-(2-imidazolin-2-yl)fluoroalkyoxy-, alkenyloxy- and alkynyloxypyridines AMERICAN CYANAMID COMPANY (US) 1987-03-03 US disclosed
EP-0166907-A2 Herbicidal 2-(2-imidazolin-2-yl)-fluoroalkoxy-, alkenyloxy- and alkynyloxypyridines and quinolines AMERICAN CYANAMID COMPANY (US) 1986-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR1 DHODH 1360/4885NAPRT 1748/4885TDP1 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.